Precipio, Inc.
No enriched coverage for $PRPO in the last 7 days.
No SEC Form 4 filings for $PRPO in the last 30 days.
See all $PRPO insider activity →Precipio Inc (PRPO) reported record Q2 2026 revenue of $7M, up 22% YoY. Adjusted EBITDA turned positive at $400K, driven by revenue growth and lower stock-based compensation. The company added new distributor reps and expects pipeline conversions to boost growth. CEO Ilan Danieli highlighted the 'flywheel' model's competitive advantage and the market potential of the AML product.
Precipio (NASDAQ: PRPO) reported Q2 2026 GAAP EPS of -$0.12 and a GAAP net loss of $0.219 million, alongside record net sales of $7.02 million, up about 24% year over year. Revenue beat the cited consensus $1.68 million. Product revenue rose to $0.906 million and adjusted EBITDA was $0.4 million. Cash at quarter-end was $3.08 million.
Precipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PR
Recent PRPO coverage spans financial news, earnings and corporate actions.
Earnings beat expectations with revenue growth and cash generation, likely supporting short‑term upside.
Beat on revenue and adjusted profitability, but GAAP remains loss-making and the 10-Q flags going-concern risk.
Q2 results show a return to positive Adjusted EBITDA and improving cash generation, which can re-rate near-term risk for PRPO.
Routine annual meeting results; modest governance/audit continuity signal with limited direct financial impact.
Technical breakdown below the 200-day MA, alongside predominantly bearish analyst ratings, increases near-term risk of further selling.
alphai scores every news story that mentions PRPO with an AI model for sentiment and relevance, and aggregates insider trades from Precipio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Precipio Inc (PRPO) reported record Q2 2026 revenue of $7M, up 22% YoY. Adjusted EBITDA turned positive at $400K, driven by revenue growth and lower stock-based compensation. The company added new distributor reps and expects pipeline conversions to boost growth. CEO Ilan Danieli highlighted the 'flywheel' model's competitive advantage and the market potential of the AML product.
3 min readPrecipio (NASDAQ: PRPO) reported Q2 2026 GAAP EPS of -$0.12 and a GAAP net loss of $0.219 million, alongside record net sales of $7.02 million, up about 24% year over year. Revenue beat the cited consensus $1.68 million. Product revenue rose to $0.906 million and adjusted EBITDA was $0.4 million. Cash at quarter-end was $3.08 million.
4 min readPrecipio, Inc. (PRPO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PR
4 min readPrecipio, Inc. (PRPO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001043961 0001043961 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of repo
2 min readPrecipio Inc. (NASDAQ:PRPO) shares fell below their 200-day moving average during Wednesday trading, trading as low as $23.44 and last at $23.55. The 200-day average is $25.08. The article cites recent analyst changes, including a downgrade to “hold” by Wall Street Zen and “sell” ratings from Weiss. Precipio reported May 14 quarterly EPS of ($0.81) on $6.71M revenue.
3 min readSANDBERG RICHARD A sold 900 indirectly-held shares of Precipio, Inc. (PRPO) at $25.02 on 2026-05-21.
1 min readPrecipio, a blood cancer diagnostics firm, announced a preliminary 23% increase in its fourth-quarter revenue. This short report, distributed by Reuters, highlights the company's Q4 financial performance.
2 min readPRPO reports strong third-quarter 2025 results with higher revenue, positive cash flow and improved margins in core divisions.
2 min readOver $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter Over $450,000 Adjusted EBITDA and $275,000 positive operating cash flow for the quarter ...
2 min readConference Call to be held on November 17th, 2025 at 5:00 PM EST Conference Call to be held on November 17th, 2025 at 5:00 PM EST ...
2 min read
